IL280745B1 - Anti-FC epsilon-R1 alpha (FCER1A) antibodies, bispecific antigen binding molecules that bind FCER1A and CD3, and their uses - Google Patents

Anti-FC epsilon-R1 alpha (FCER1A) antibodies, bispecific antigen binding molecules that bind FCER1A and CD3, and their uses

Info

Publication number
IL280745B1
IL280745B1 IL280745A IL28074521A IL280745B1 IL 280745 B1 IL280745 B1 IL 280745B1 IL 280745 A IL280745 A IL 280745A IL 28074521 A IL28074521 A IL 28074521A IL 280745 B1 IL280745 B1 IL 280745B1
Authority
IL
Israel
Prior art keywords
antigen
amino acid
binding
seq
acid sequence
Prior art date
Application number
IL280745A
Other languages
English (en)
Hebrew (he)
Other versions
IL280745A (en
Inventor
Jamie M Orengo
Andre Limnander
Jee H Kim
Andrew J Murphy
Original Assignee
Regeneron Pharma
Jamie M Orengo
Andre Limnander
Jee H Kim
Andrew J Murphy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Jamie M Orengo, Andre Limnander, Jee H Kim, Andrew J Murphy filed Critical Regeneron Pharma
Publication of IL280745A publication Critical patent/IL280745A/en
Publication of IL280745B1 publication Critical patent/IL280745B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL280745A 2018-08-23 2019-08-22 Anti-FC epsilon-R1 alpha (FCER1A) antibodies, bispecific antigen binding molecules that bind FCER1A and CD3, and their uses IL280745B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721921P 2018-08-23 2018-08-23
PCT/US2019/047601 WO2020041537A1 (en) 2018-08-23 2019-08-22 Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof

Publications (2)

Publication Number Publication Date
IL280745A IL280745A (en) 2021-04-29
IL280745B1 true IL280745B1 (en) 2026-02-01

Family

ID=67876086

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280745A IL280745B1 (en) 2018-08-23 2019-08-22 Anti-FC epsilon-R1 alpha (FCER1A) antibodies, bispecific antigen binding molecules that bind FCER1A and CD3, and their uses

Country Status (18)

Country Link
US (2) US11578127B2 (https=)
EP (1) EP3840841A1 (https=)
JP (2) JP7402223B2 (https=)
KR (1) KR20210049863A (https=)
CN (1) CN112888482B (https=)
AU (1) AU2019325565B2 (https=)
BR (1) BR112021003023A2 (https=)
CA (1) CA3109513A1 (https=)
CL (2) CL2021000437A1 (https=)
CO (1) CO2021003608A2 (https=)
EA (1) EA202190601A1 (https=)
IL (1) IL280745B1 (https=)
MX (1) MX2021002165A (https=)
MY (1) MY204368A (https=)
PH (1) PH12021550322A1 (https=)
SG (1) SG11202101608XA (https=)
WO (1) WO2020041537A1 (https=)
ZA (1) ZA202100919B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3840841A1 (en) 2018-08-23 2021-06-30 Regeneron Pharmaceuticals, Inc. Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
WO2021159128A2 (en) * 2020-01-31 2021-08-12 Randy Leiman Allen Methods and kit for detection of analytes
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO2006028956A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US9868786B2 (en) * 2011-04-12 2018-01-16 University Of Cincinnati Methods for suppressing allergic reactions
WO2012169741A2 (ko) 2011-06-07 2012-12-13 (주)네오팜 ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN104293738A (zh) 2013-09-11 2015-01-21 李莉 一种抗人FcεRⅠα亚基单克隆抗体及其应用
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
CA2957850A1 (en) 2014-08-13 2016-02-18 Suppremol Gmbh Antibodies comprising binding domains to fc.epsilon. receptor (fc.epsilon.r) and fc gamma receptor iib (fc.gamma.riib)
CN104800164B (zh) 2015-04-13 2017-11-07 上海市第一人民医院 一种雷公藤免疫纳米粒及用途
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
IL262241B2 (en) * 2016-04-13 2024-05-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
MY194596A (en) 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
EP3840841A1 (en) 2018-08-23 2021-06-30 Regeneron Pharmaceuticals, Inc. Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HONG, JUNG YEON ET AL., "ANTIBODY TO FC?RI? SUPPRESSES IMMUNOGLOBULIN E BINDING TO HIGH-AFFINITY RECEPTOR I IN ALLERGIC INFLAMMATION", 1 November 2016 (2016-11-01) *
LINV, PING, ET AL., HIGH AFFINITY HUMAN IGE RECEPTOR (FCRRI), 15 June 1999 (1999-06-15) *

Also Published As

Publication number Publication date
SG11202101608XA (en) 2021-03-30
CA3109513A1 (en) 2020-02-27
IL280745A (en) 2021-04-29
NZ772900A (en) 2025-05-02
CO2021003608A2 (es) 2021-04-30
US20200062844A1 (en) 2020-02-27
JP2021533806A (ja) 2021-12-09
BR112021003023A2 (pt) 2021-05-11
CL2021000437A1 (es) 2021-09-03
JP2023171909A (ja) 2023-12-05
AU2019325565A1 (en) 2021-03-11
WO2020041537A8 (en) 2020-09-10
US11578127B2 (en) 2023-02-14
CN112888482A (zh) 2021-06-01
AU2019325565B2 (en) 2025-09-04
US20230331845A1 (en) 2023-10-19
ZA202100919B (en) 2025-10-29
JP7402223B2 (ja) 2023-12-20
EA202190601A1 (ru) 2021-07-14
MY204368A (en) 2024-08-26
KR20210049863A (ko) 2021-05-06
EP3840841A1 (en) 2021-06-30
CL2023000442A1 (es) 2023-11-24
WO2020041537A1 (en) 2020-02-27
US12441797B2 (en) 2025-10-14
JP7541167B2 (ja) 2024-08-27
MX2021002165A (es) 2021-07-16
CN112888482B (zh) 2024-06-25
PH12021550322A1 (en) 2021-10-04

Similar Documents

Publication Publication Date Title
US12252530B2 (en) Human antibodies to Fel d1 and methods of use thereof
US11542326B2 (en) Anti-IL-25 antibodies and uses thereof
EP3683235B1 (en) Anti-il-33 antibodies and uses thereof
JP7034068B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
CN112423785A (zh) 双特异性抗BCMAx抗CD3抗体及其用途
US12441797B2 (en) Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bind FCϵR1α and CD3, and uses thereof
HK40114832A (en) Anti-il-33 antibodies and uses thereof
HK40032431B (en) Anti-il-33 antibodies and uses thereof
HK40032431A (en) Anti-il-33 antibodies and uses thereof
NZ710831B2 (en) Anti-il-33 antibodies and uses thereof